Drugs / GSK2798745
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04292912 | Sep 2020 → Apr 2022 | macular retinal edema | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT03511105 | Jun → Dec 2018 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02925546 | Oct → Dec 2016 | congestive heart failure | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03372603 | Apr → Oct 2018 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02497937 | Apr 2016 → Aug 2017 | heart failure | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT02119260 | Jun 2014 → Dec 2016 | pulmonary edema | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2798745 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03511105 ↗ |
| Action | Inhibit | “GSK2798745 is a first-in-class, highly potent, selective, orally active TRPV4 channel blocker being evaluated in a first-time-in-humans study (NCT02119260).” PMID 30637626 ↗ Jun 2019 |
| Modality | Small molecule | — CHEMBL4470585 ↗ |
| Route | Oral | “given as single and repeat oral doses to healthy subjects and stable heart failure (HF) subjects.” NCT02119260 ↗ |
| Target | TRPV4 | “In blocking the TRPV4 ion channel and reducing pulmonary interstitial fluid” NCT02497937 ↗ |